Latest Breaking News On - Prnewswire fusion pharmaceuticals inc - Page 8 : comparemela.com

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAmanda crayseniorJohn valliantFusion pharmaceuticals incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsAnnual cowen healthcare conferenceChief executive officer john valliantResponse inhibitorsAmanda craysenior directorInvestor relationsCorporate communications

Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesMohit rawatJohn valliantChristopher leamonAmanda crayFusion pharmaceuticals incNiowave incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsVirtual global biopharma conferenceChief executive officer john valliantChief scientific officer christopher leamonChief business officer mohitRepair inhibitorsInvestor relations

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.

United statesEbrahim delpassandJohn valliantAmanda crayFusion pharmaceuticals incMorgan stanleySpica centerDeerfield management companyLaborde professor for cancer researchPrnewswire fusion pharmaceuticals incRadiomedix incFusion pharmaceuticalsWoodline master fundNiowave incTulane cancer centerExchange commission

Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayFusion pharmaceuticals incNiowave incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsChief executive officer john valliantResponse inhibitorsPrivate securities litigation reform actInvestor relationsFusion pharmaceuticals inc

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that.

John valliantJonathan cirtainAmanda crayFusion pharmaceuticals incMcmaster universityTechnologies incFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsChief executive officer john valliantChief executive officer jonathan cirtainResponse inhibitorsOntario based mcmaster universityGood manufacturing practiceDefense news topPrivate securities litigation reform act